Suggestions will update as you type

Support for your eligible patients is here*

*Lilly Support Services for Inluriyo programs and services are not a guarantee of coverage. Terms and conditions apply for all programs. See the Lilly Support Services for Inluriyo Enrollment Form for details.

Woman looking ahead with confident expression

Inluriyo Savings Card

Inluriyo Savings Card icon.

Patients pay as little as $0 a month if eligible and commercially insured with coverage for Inluriyo*

*Month is defined as 28 days.

Terms and Conditions

By enrolling in and using the Inluriyo Savings Card Program (“Program”) and using the Inluriyo Savings Card (“Card”), you attest that you meet the eligibility criteria, and you agree to comply with the terms and conditions described below:

Card Eligibility:

  1. You have been prescribed Inluriyo (imlunestrant) for an approved use consistent with FDA approved product labeling;
  2. You are enrolled in a commercial drug insurance plan and have coverage for Inluriyo;
  3. You are not enrolled in any state, federal, or government funded healthcare program, including, without limitation, Medicaid, Medicare, Medicare Part D, Medicare Advantage, Medigap, DoD, VA, TRICARE®/CHAMPUS, or any state prescription drug assistance program;
  4. You are a resident of the United States or Puerto Rico; and
  5. You are 18 years of age or older.

Card Terms and Conditions

For patients with commercial drug insurance coverage for Inluriyo: You must have commercial drug insurance that covers Inluriyo and a prescription for an approved use consistent with FDA-approved product labeling to pay as little as $0 for a 1-month prescription fill of Inluriyo. Month is defined as 28 days. Card savings are subject to a maximum monthly savings of wholesale acquisition cost plus usual and customary pharmacy charges and separate maximum annual savings of up to $10,600 per calendar year. Card may be used for a maximum of up to 14 prescription fills per calendar year. Except where prohibited by applicable state law, Card monthly and annual savings are reduced if Lilly identifies that you are enrolled in a plan or program, sometimes called a maximizer plan, that adjusts your cost sharing amount to be equal to or include some portion of the savings provided by the Card and attempts to prevent the savings from this Card from being applied to your out-of-pocket costs, including but not limited to copayments, coinsurances, and deductibles (“Maximizer”). If the Program identifies you are enrolled in a Maximizer, Card savings are reduced to a maximum monthly savings of up to $25 and a separate maximum annual savings of up to $350 per calendar year. If you have reason to believe that the Program erroneously identified enrollment in a Maximizer, please call the Inluriyo Savings Card Program at 1-844-583-3550. Subject to Lilly USA, LLC’s (“Lilly”) right to terminate, rescind, revoke, or amend Card eligibility criteria and/or Card terms and conditions which may occur at Lilly’s sole discretion, without notice, and for any reason. Card expires and savings end on 12/31/2026.

Additional Program Terms and Conditions

If you have an insurance plan that is participating in an alternate funding program (“AFP”) that requires you to apply to the Inluriyo Savings Card Program or otherwise pursue specialty drug prescription coverage through an alternate funding vendor as a condition of, requirement for, or prerequisite to coverage of Inluriyo, you are not eligible for and are prohibited from using the Inluriyo Savings Card Program. AFPs include programs where coverage, reimbursement, or patient out of pocket costs for a product in some way vary based on the availability of a manufacturer co-pay program. AFPs may modify, delay, deny, restrict, or withhold insurance benefits or coverage from patients, or exclude Lilly products from coverage contingent upon a member’s use of Inluriyo Savings Card Program. You agree to inform the Inluriyo Savings Card Program if you are or become a member of such an alternative funding program. You are responsible for any applicable taxes, fees, and any amount that exceeds the monthly or annual maximum Card savings. Monthly and annual maximum savings are set at Lilly’s sole and absolute discretion and may be changed with or without notice at any time for any reason. At its sole discretion and with or without notice, Lilly may reduce, eliminate, or otherwise modify the Card savings for any reason, including but not limited to if your commercial drug insurance plan imposes additional requirements which limits or prevents you from receiving coverage for Inluriyo, only allows partial coverage for Inluriyo, removes coverage for Inluriyo and requires you to utilize the Card, does not provide a material level of financial assistance for the cost of Inluriyo, or does not apply Card payments to satisfy your co-payment, deductible, or coinsurance for Inluriyo. Card savings are not valid for: Massachusetts residents if an AB-rated generic equivalent is available; California residents if an FDA-approved therapeutic equivalent is available. You must meet the Card eligibility criteria, terms and conditions every time you use the Card. If at any time you begin receiving drug coverage under any state, federal, or government funded healthcare program, you understand that you will no longer be eligible for the Inluriyo Savings Card and agree to call the Inluriyo Savings Card Program at 1-844-583-3550 to stop participation. Card activation is required. You may not seek reimbursement from your health insurance, any third party, or any health savings, flexible spending, or other healthcare reimbursement accounts, for any amount of the savings received through the Card. By utilizing the Card, you agree that if you are required to do so under the terms of your insurance coverage for this prescription or are otherwise required to do so by law, you will notify your Insurance Carrier of your redemption of the Card. Card savings cannot be combined or utilized with any other program, discount, discount card, cash discount card, coupon, incentive, or similar offer involving Inluriyo. You agree that this Card savings is intended solely for the benefit of you, the patient, and that the Card benefits are non-transferable. It is prohibited for any person to sell, purchase, or trade; or to offer to sell, purchase, or trade, or to counterfeit the Card.THIS CARD IS NOT INSURANCE. Lilly has the sole right to interpret and apply Card eligibility criteria, and terms and conditions. Card eligibility, and terms and conditions may be terminated, rescinded, revoked, or amended by Lilly at any time without notice and for any reason. Lilly’s sole discretion to terminate, rescind, revoke, or amend Card eligibility and/or Card terms and conditions includes the right to terminate any individual Card if Lilly determines, in its sole discretion, that a patient does not satisfy the Card’s eligibility criteria or is using or has attempted to use the Card inconsistently with these terms and conditions. Eligibility criteria, and terms and conditions for the Inluriyo Savings Card Program may change from time to time; the most current version can be found at https://www.inluriyo.lilly.com/savings-support#terms-and-conditions. You may be required to obtain a new Card, including if any Card terms and conditions have been terminated, rescinded, revoked, or amended by Lilly. Card void where prohibited by law. Subject to Lilly’s right to terminate, rescind, revoke or amend Card eligibility criteria and/or Card terms and conditions which may occur at Lilly’s sole discretion, without notice, and for any reason. Card expires and savings end on 12/31/2026.

TRICARE® is a registered trademark of the Department of Defense (DoD), DHA.

Lilly Support Services for Inluriyo (imlunestrant)*

A support program tailored to your eligible patients.

If you have questions about Lilly Support Services for Inluriyo, please call 1-800-LillyRx (1-800-545-5979) from Monday to Friday.

*Lilly Support Services for Inluriyo programs and services are not a guarantee of coverage. Terms and conditions apply for all programs.

Interim Access Program for Inluriyo (imlunestrant)

Medication Icon

The Inluriyo Interim Access Program may provide a temporary supply of Inluriyo at no cost to insured, eligible patients who have been prescribed Inluriyo for the first time and are experiencing a delay in their insurance coverage decision. See terms and conditions below.

TERMS AND CONDITIONS: The Inluriyo Interim Access Program (or “Program”) provides a 14-day supply of Inluriyo at no charge for eligible, insured patients who are: 1) prescribed Inluriyo for the first time, 2) experiencing a minimum 5-business-day delay in insurance coverage determination, 3) prescribed Inluriyo for an FDA-approved indication or an indication medically supported by CMS-recognized compendia, 4) enrolled in Lilly Support Services™, and 5) residents of the United States or Puerto Rico. May not be combined with any other offer. Not available to patients whose insurers have made a final determination to deny the patient coverage for Inluriyo. If a denial is received after the initial 5 business days have passed and appeal rights are being pursued, or if there is a persistent coverage delay, the patient, under appropriate circumstances, may be eligible for up to 3 additional 14-day supplies of Inluriyo. Product provided through the Program is only available through the Program noncommercial specialty pharmacy. Product is provided free of charge and may not be sold, bartered, or returned for credit. Reimbursement cannot be sought from any third party for product provided under the Program. Patients enrolled in Medicare Part D are prohibited from counting any portion of the cost of the product provided under the Program toward true out-of-pocket (“TrOOP”) costs for prescription drug calculations. No purchase contingency or other obligation accompanies Program participation. This Program is not health insurance and does not guarantee coverage. Lilly reserves the right to change or end the Program at any time. Benefits under the Program are not transferable.

CMS=Centers for Medicare & Medicaid Services; FDA=US Food and Drug Administration.

Assistance Determining Insurance Coverage

Coverage icon

May help eligible patients prescribed Inluriyo™ (imlunestrant) minimize copay or out-of-pocket costs by providing:

  • A benefits investigation
    • Helps eligible enrolled patients prescribed Inluriyo understand their coverage options, locate the appropriate specialty pharmacy, and identify their lowest possible out-of-pocket cost
  • Guidance through the specialty pharmacy process
  • An overview of potential savings opportunities

Lilly Support Services for Inluriyo programs and services are not a guarantee of coverage. Terms and conditions apply for all programs. See the Lilly Support Services for Inluriyo Enrollment Form for details.

Access Resources

Ordering Inluriyo

Inluriyo can be purchased from authorized distributors and is available through:

Pharmacy icon

Contracted specialty pharmacies§

Hospital icon

Hospital and health system practices

Healthcare provider icon

In-office dispensing (IOD) practices

§Eligible pharmacies can purchase Inluriyo through authorized distribution partners. A list of authorized distributors can be found at trade.lilly.com.

Reimbursement guide icon

Inluriyo Access, Reimbursement, and Distribution Guide

The access and reimbursement landscape can be complex and cumbersome. Information within the guide can help you navigate the complexities of the reimbursement landscape.

Authorization letter icon

Coverage Authorization
Appeals Letter

If an initial claim or coverage authorization request letter is denied, the payer may require a coverage authorization appeals letter.

Medical necessity letter icon

Letter of Medical Necessity (LMN)

Many health plans require that an LMN accompany a coverage authorization appeals letter.

EHR Resources - Electronic Order Sets

Computer monitor icon

Easy-to-use, step-by-step downloadable instructions to develop Inluriyo electronic order sets in your EHR system.

If your system is not listed, please download the Treatment Plan Guide to help develop Inluriyo electronic order sets.

ehr=electronic health records

INDICATION

Inluriyo is indicated for the treatment of adults with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, estrogen receptor-1 (ESR1)-mutated advanced or metastatic breast cancer with disease progression following at least one line of endocrine therapy.1

IMPORTANT SAFETY INFORMATION FOR INLURIYO™ (imlunestrant)

Warnings and Precautions - Embryo-Fetal Toxicity

Based on findings in animals and its mechanism of action, Inluriyo can cause fetal harm when administered to a pregnant woman. In an animal reproduction study, oral administration of imlunestrant to pregnant rats during the period of organogenesis led to embryo-fetal mortality and structural abnormalities at maternal exposures that were below the human exposure at the recommended dose based on area under the curve (AUC). Avoid the use of imlunestrant in pregnant women. Advise pregnant women and females of reproductive potential of the potential risk to a fetus. Advise females of reproductive potential and males with female partners of reproductive potential to use effective contraception during treatment with Inluriyo and for 1 week after the last dose.

Serious and Fatal Adverse Reactions

Serious adverse reactions occurred in 10% of patients who received Inluriyo. Serious adverse reactions in >1% of patients included pleural effusion (1.2%). Fatal adverse reactions occurred in 1.8% of patients who received Inluriyo, including cardiac arrest, acute myocardial infarction, right ventricular failure, hypovolemic shock, and upper gastrointestinal hemorrhage (each 0.3%).

Most Common Adverse Reactions

The most common adverse reactions (incidence ≥10%), including laboratory abnormalities, in patients who received Inluriyo were: hemoglobin decreased (30%), musculoskeletal pain (30%), calcium decreased (26%), neutrophils decreased (26%), AST increased (25%), fatigue (23%), diarrhea (22%), ALT increased (21%), triglycerides increased (21%), nausea (17%), platelets decreased (16%), constipation (10%), cholesterol increased (10%), and abdominal pain (10%).

Drug Interactions

Imlunestrant is a CYP3A substrate. Avoid concomitant use of Inluriyo with strong CYP3A inhibitors. If concomitant use cannot be avoided, reduce the dosage of Inluriyo. Avoid concomitant use of Inluriyo with strong CYP3A inducers. If concomitant use cannot be avoided, increase the dosage of Inluriyo.

Imlunestrant inhibits both P-gp and BCRP. Avoid concomitant use unless otherwise recommended in the Prescribing Information for P-gp or BCRP substrates where minimal concentration changes may lead to serious adverse reactions.

Use in Specific Populations - Lactation

Because of the potential for serious adverse reactions in the breastfed child, advise lactating women to not breastfeed during treatment with Inluriyo and for 1 week after the last dose.

Use in Specific Populations - Hepatic Impairment

Reduce the dose of Inluriyo for patients with moderate (Child-Pugh B) or severe (Child-Pugh C) hepatic impairment. No dosage adjustment is recommended for patients with mild hepatic impairment (Child-Pugh A).

Inluriyo (imlunestrant) is available as 200 mg tablets.

Please click to access Prescribing Information for Inluriyo.

IN HCP ISI M APP